Clinical, Cosmetic and Investigational Dermatology (Jul 2022)
Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
Abstract
Carol Sanchez,1 Jonette Keri1,2 1University of Miami Department of Cutaneous Surgery and Dermatology, Miami, FL, USA; 2Miami Veterans Affairs Medical Center, Miami, FL, USACorrespondence: Carol Sanchez, University of Miami Department of Cutaneous Surgery and Dermatology, 7815 NW 104 AVE, Doral, Miami, FL, 33178, USA, Email [email protected]: The purpose of this narrative review is to provide a summary of the clinical trials on the efficacy and safety of clascoterone 1% cream (Winlevi) to grant providers an understanding of which patients will benefit most from this novel topical antiandrogen medication. Clascoterone 1% cream (Winlevi) offers a new and exciting treatment approach for a difficult and common skin condition such as acne vulgaris. This topical androgen antagonist is the first of its kind but will hopefully provoke investigations into other androgen receptor antagonists with similar or better efficacy.Keywords: hormonal acne, anti-androgens, CB-03-01, Winlevi
